
|Videos|September 6, 2017
Dr. Rosenberg Discusses the Importance of Clinical Trials in Bladder Cancer
Author(s)Jonathan E. Rosenberg, MD
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.
Advertisement
Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.
There is a long history of failed adjuvant clinical trials in bladder cancer due to poor accrual, says Rosenberg. He says that is important for treating physicians to recommend patients for these trials in order to test novel adjuvant therapies.
Adjuvant immunotherapy trials are showing greater success in accrual though, Rosenberg adds.
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5




































